Clinical trials: Hyperlipoproteinemia
Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
This is a multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluating the efficacy and safety of IBI306 monotherapy in Chinese Paricipants with non-familial hypercholesterolemia and mixed…
- Trial name
- NCT07473960
- Testing
- IBI306
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hyperlipidemia, Hypertension
Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia
To evaluate efficacy and safety of YH16410 versus rosuvastatin and telmisartan monotherapies in patients with hypertension and hyperlipidemia
- Trial name
- NCT01914432
- Testing
- YH16410, Rosuvastatin, Telmisartan
- Where
- South Korea
- Volunteers
- 210 people
- Sponsor
- Yuhan Corporation
Hyperlipidemia
A Study to Evaluate COR-1004 in Adult Volunteers.
This research study is being done to see if a new, injectable drug called COR-1004 is safe for people to take. It will also help doctors find the right dose of the drug.
- Trial name
- NCT07229118
- Testing
- COR-1004
- Where
- 2 sites in New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Essential Hypertension, Hyperlipidemia
Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
The purpose of this study is to evaluate efficacy and safety of HL-040XC in patients with essential hypertension and hyperlipidemia
- Trial name
- NCT01541943
- Testing
- Atorvastatin, Losartan, HL-040XC
- Where
- South Korea
- Volunteers
- 356 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Atherosclerosis, Hypercholesterolemia
Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)
The purpose of the study is to determine whether ezetimibe plus simvastatin will be more effective than simvastatin alone in preventing progression of atherosclerosis of the inner layer of the carotid artery.
- Conditions
- Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II
- Trial name
- ENHANCE (NCT00552097)
- Testing
- ezetimibe (plus simvastatin)
- Volunteers
- 720 people
- Sponsor
- Organon and Co
Hyperlipidemias
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels
The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.
- Trial name
- NCT00813527
- Testing
- Lapaquistat acetate and fenofibrate, Fenofibrate
- Where
- 36 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Takeda
Hypertension, Hyperlipidemia
Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
A phase 3 study to evaluate efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia
- Trial name
- NCT02899455
- Testing
- HGP0904, HGP0608, HGP0816
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
The purpose of this study is to investigate the effect of Atorvastatin on the pharmacokinetic properties of Telmisartan/S-amlodipine
- Trial name
- CKD-345 DDI (NCT01842230)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, Telmisartan 80mg and S-amlodipine 5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Acute Coronary Syndrome
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS)…
- Trial name
- V-INCEPTION (NCT04873934)
- Testing
- Inclisiran
- Where
- 88 sites in United States
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Familial Hypercholesterolemia
A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)
This study is a non-interventional (observational) study in Japan to confirm the safety and efficacy of Zetia when administered alone or in combination with other lipid-lowering drugs in daily medical practice throughout a…
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia
- Trial name
- NCT00705211
- Testing
- Ezetimibe, Ezetimibe + other lipid-lowering medication(s)
- Volunteers
- 1,794 people
- Sponsor
- Organon and Co
Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy.
- Conditions
- Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia, Hypercholesterolemia
- Trial name
- NCT06112327
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 116 people
- Sponsor
- Verve Therapeutics, Inc.
Obesity
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
The purpose of this study is to compare the efficacy and safety of topiramate (96, 192, and 256mg daily) with placebo in long-term treatment of obesity.
- Trial name
- NCT00236639
- Testing
- topiramate
- Volunteers
- 1,293 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are…
- Trial name
- SPIRE-SI (NCT02135029)
- Testing
- Bococizumab (PF-04950615;RN316), Atorvastatin
- Where
- 40 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- Pfizer
Dyslipidemias, High Cholesterol
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- BROOKLYN (NCT05425745)
- Testing
- Obicetrapib
- Where
- 96 sites in United States, Canada and 8 more
- Volunteers
- 354 people
- Sponsor
- NewAmsterdam Pharma
Homozygous Familial Hypercholesterolemia
Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3- LRX for reduction of low density lipoprotein cholesterol (LDL-C) levels in patients with Homozygous Familial Hypercholesterolemia (HoFH).
- Trial name
- NCT03455777
- Testing
- AKCEA-ANGPTL3-LRX
- Where
- Canada
- Sponsor
- Akcea Therapeutics
Homozygous Familial Hypercholesterolemia
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.
- Trial name
- ORION-2 (NCT02963311)
- Testing
- ALN-PCSSC, Standard of Care
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 9 people
- Sponsor
- The Medicines Company
Hyperlipoproteinemia (a)
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or…
- Trial name
- NCT07172646
- Testing
- SRSD216 injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sirius Therapeutics Co., Ltd.
Hypercholesterolemia
Single Dose Study of PF-06815345 in Healthy Subjects
The current study is the first clinical trial proposed with PF-06815345. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single oral doses of PF-06815345 to healthy adult…
- Trial name
- NCT02654899
- Testing
- PF-06815345
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertriglyceridemia, Mixed Hyperlipidemia
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
The purpose of this pilot study is to learn what study factors are important in designing a large, full-scale study of the effects of TRIA-662 on serum triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) levels.
- Trial name
- NCT02008084
- Testing
- TRIA-662
- Where
- 17 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Cortria Corporation
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
A Open-label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin versus Co-administration of a Fixed Dose Combination of…
- Trial name
- NCT02569814
- Testing
- Fimasartan/Amlodipine/Rosuvastatin, Fimasartan/Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd